AC Immune SA ACIU
NASDAQ
| 06/30/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 4.28M | 5.15M | 33.44M | 32.62M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 4.28M | 5.15M | 33.44M | 32.62M |
| Cost of Revenue | -- | 67.74M | 72.42M | 72.82M | 71.37M |
| Gross Profit | -- | -63.46M | -67.26M | -39.38M | -38.75M |
| SG&A Expenses | -- | 19.37M | 18.66M | 18.54M | 18.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -117.00K | -41.50K | -63.50K | -82.10K |
| Total Operating Expenses | -- | 86.99M | 91.03M | 91.29M | 90.14M |
| Operating Income | -- | -82.71M | -85.88M | -57.85M | -57.52M |
| Income Before Tax | -- | -84.67M | -84.66M | -58.48M | -57.96M |
| Income Tax Expenses | -- | -- | 3.40K | 3.40K | 3.40K |
| Earnings from Continuing Operations | -- | -84.67 | -84.67 | -58.48 | -57.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -84.67M | -84.67M | -58.48M | -57.96M |
| EBIT | -- | -82.71M | -85.88M | -57.85M | -57.52M |
| EBITDA | -- | -81.03M | -84.20M | -56.18M | -55.88M |
| EPS Basic | -- | -0.84 | -0.85 | -0.58 | -0.58 |
| Normalized Basic EPS | -- | -0.40 | -0.40 | -0.36 | -0.36 |
| EPS Diluted | -- | -0.84 | -0.85 | -0.59 | -0.59 |
| Normalized Diluted EPS | -- | -0.40 | -0.40 | -0.36 | -0.36 |
| Average Basic Shares Outstanding | -- | 401.22M | 400.14M | 400.87M | 399.79M |
| Average Diluted Shares Outstanding | -- | 401.22M | 400.14M | 401.89M | 400.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |